prikaz prve stranice dokumenta Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
  Preuzmi
PDF 903.4 KB
Znanstveni rad - Pregledni rad
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
World Journal of Clinical Cases, 10 (2022), 20; 6759-6768. https://doi.org/10.12998/wjcc.v10.i20.6759
Cigrovski Berković, Maja; Režić, Tanja; Bilić-Ćurčić, Ines; Mrzljak, Anna

Citirajte ovaj rad

Cigrovski Berković, M., Režić, T., Bilić Ćurčić, I. i Mrzljak, A. (2022). Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases, 10. (20), 6759-6768. doi: 10.12998/wjcc.v10.i20.6759

Cigrovski Berković, Maja, et al. "Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?." World Journal of Clinical Cases, vol. 10, br. 20, 2022, str. 6759-6768. https://doi.org/10.12998/wjcc.v10.i20.6759

Cigrovski Berković, Maja, Tanja Režić, Ines Bilić Ćurčić i Anna Mrzljak. "Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?." World Journal of Clinical Cases 10, br. 20 (2022): 6759-6768. https://doi.org/10.12998/wjcc.v10.i20.6759

Cigrovski Berković, M., et al. (2022) 'Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?', World Journal of Clinical Cases, 10(20), str. 6759-6768. doi: 10.12998/wjcc.v10.i20.6759

Cigrovski Berković M, Režić T, Bilić Ćurčić I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases [Internet]. 16.07.2022. [pristupljeno 22.04.2024.];10(20):6759-6768. doi: 10.12998/wjcc.v10.i20.6759

M. Cigrovski Berković, T. Režić, I. Bilić Ćurčić i A. Mrzljak, "Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?", World Journal of Clinical Cases, vol. 10, br. 20, str. 6759-6768, Srpanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:322589. [Citirano: 22.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:322589
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
AutorMaja Cigrovski Berković
AutorTanja Režić
AutorInes Bilić-Ćurčić
AutorAnna Mrzljak
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Metabolically associated fatty liver disease (MAFLD) is a liver manifestation of metabolic syndrome potentially related to unfavorable hepatic and extrahepatic outcomes and progression to cirrhosis. Up to date, there are no approved pharmacotherapies for the treatment of MAFLD, so management focused on lifestyle interventions to encourage weight loss, and treatment of coexisting conditions is the only available option. Unfortunately, the aforementioned is often not potent enough to offer reversal or slow down hepatic inflammation and fibrosis. Glucagon-like peptide-1 receptor agonists have a favorable effect on glycemic management and weight loss of patients with type 2 diabetes mellitus and recently published data suggest their potential in MAFLD treatment. In addition, some of the agents have proven cardiovascular and renal benefits in dedicated cardiovascular outcome trials, making them an interesting therapeutic option. In this opinion review, we discuss the role of semaglutide in MAFLD.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaWorld Journal of Clinical Cases
Brojčani podacivol. 10, br. 20, str. 6759-6768
p-ISSN2307-8960
DOIhttps://doi.org/10.12998/wjcc.v10.i20.6759
URN:NBNurn:nbn:hr:105:322589
Datum objave publikacije2022-07-16
URL dokumentahttps://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2023-02-21 08:12:10